乙型肝炎病毒(HBV)感染是最严重危害健康问题之一,全球约有3.5亿慢性HBV携带者,中国约占1/3。由于HBV导致的疾病负担已成为一个很大的挑战,统计显示HBV感染致生命及健康投资大量流失,在中国的慢性HBV携带者中,至少2 000万活动性肝病患者需抗病毒治疗。对慢乙肝患者治疗抗病毒已被认为是主要的治疗手段,中药和对症或支持治疗则作为辅助治疗,慢乙肝治疗目标是获得乙肝病毒持续抑制,减轻肝脏疾病活动和阻止或延缓肝硬化. Hepatitis B virus (HBV) infection is one of the most serious health hazards, there are about 350 million chronic HBV carriers around the world, accounting for about 1/3 of China. Since the burden of disease caused by HBV has become a big challenge, statistics show that a substantial loss of life and health investment from HBV infection has resulted in the need for antiviral treatment of at least 20 million patients with active liver disease among chronic HBV carriers in China. Treatment of chronic hepatitis B patients with antiviral therapy has been considered as the main treatment of traditional Chinese medicine and symptomatic or supportive treatment as adjuvant therapy, chronic hepatitis B treatment goal is to obtain sustained inhibition of hepatitis B virus, reduce liver disease activity and prevent or delay cirrhosis.